The Health Department in Gauteng has started processing payment of striking AIDS counsellors and home-based carers, but has failed to fulfill its undertaking that all workers would have been paid by now. And the workers say they will remain on strike until all of them have been paid.
The latest edition of the KwaZulu-Natal HIV-911 Directory of HIV-Related Services is now available. The directory contains information on 2 297 organisations actively involved in HIV, TB and STI-related prevention, treatment and support in the province. It also includes information on organisations providing socio-economic, legal and psycho-social support programmes. Service provider information is categorised by municipality and type of service offered. The database is updated on an annual basis .
Since the emergence of TB and HIV co-infections, public health officials have been asking the same questions'€”how do we screen for, diagnose, and prevent TB in people living with HIV? An article tries to answer this question.
SA government policy gets support from researchers at UCT and University of East Anglia, who identify nurses as preferred health providers for ART programmes.
Repeated promises by the Gauteng Health Department to pay lay counsellors and home-based care givers who have gone without their monthly stipends of R1 500 for four months have still not materialised. The 6000-plus volunteers have voiced their frustration over the non-payment.
If men who have sex with men (MSM) have the option of using rapid HIV testing to screen potential sexual partners, will they do so?
Providing free school uniforms to enable children to stay in school, in addition to exposing primary school students to the national HIV/AIDS prevention curriculum, appeared to have a greater effect on reducing risky sexual behaviours among youth and in particular girls in Western Kenya than either intervention alone, Dr Vandana Sharma reported on Wednesday at the 19th International AIDS Conference (AIDS 2012) in Washington.
Existing treatment and prevention techniques could prevent millions of new HIV infections and deaths from AIDS -- but only if Obama sustains funding. By Mark Harrington
New research published Online First in The Lancet suggests that drug-resistant HIV has been increasing in parts of Sub-Saharan Africa since the roll-out of antiretroviral therapy (ART) nearly a decade ago.
WASHINGTON'€” A novel approach to discover the first new tuberculosis (TB) combination drug regimen cleared a major hurdle when Phase II clinical trial results found it could kill more than 99 percent of patients' TB bacteria within two weeks and could be more effective than existing treatments, according to a study published today in the Lancet. These results add to a growing body of evidence that the new regimen could reduce treatment by more than a year for some patients.
Despite substantial progress in tackling the HIV epidemic worldwide in the past two decades, there is one population in which the epidemic continues to grow in countries of all incomes: men who have sex with men (MSM). A six-part Series by THE LANCET, explore the unique aspects of the HIV epidemic in MSM, showing that factors such as the biology of HIV transmission in anal sex and the characteristics of MSM networks, as well as known behavioural factors, are driving the epidemic in this population.
A number of papers are carrying stories about the prospects for an HIV cure - this commentary in The Lancet explains what the Berlin patient has taught us.
The young TB patients at Cape Town'€™s Brooklyn Chest Hospital will be able to cosy up this winter following donations of warm clothes, toys and baby food. By Kim Cloete.
South African HIV Clinicians have welcomed an announcement that the Food and Drug Administration (FDA) in the United States has approved the use of an antiretroviral by sexually active HIV-negative men and women as a method of reducing the risk HIV infection in adults.
People at high risk of HIV infection can reduce their risk of acquiring the disease by taking antiretroviral drugs, according to Cochrane researchers.
Be in the know with our free weekly newsletter. We deliver a round-up of our top stories and insightful reads from across the web.